Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET

Company Participants

Marek Ciszewski - SVP, IR

Denny Lanfear - CEO

Theresa Lavallee - Chief Development Officer

Rosh Dias - Chief Medical Officer

Paul Reider - Chief Commercial Officer

McDavid Stilwell - CFO

Conference Call Participants

Salim Syed - Mizuho

Douglas Tsao - HC Wainwright

Chris Schott - JPMorgan

Jason Gerberry - Bank of America

Ash Verma - UBS

Operator

Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call. [Operator Instructions]

I would now like to hand the call over to SVP, Investor Relations, Marek Ciszewski. Please go ahead.

Marek Ciszewski

Thank you, Latif, and good afternoon, everyone, and thank you for joining us. We issued a press release earlier today announcing our financial results for the fourth quarter of 2022. This release can be found on the Coherus Biosciences' website and is also attached to our Form 8-K.

Today's call includes forward-looking statements regarding Coherus' current expectations about future events. These statements include but are not limited to our ability to gain approval for multiple new products and launch them, the ability of the FDA to complete required inspections in China for our BLA for Toripalimab, timing of the end of our decline in revenues and timing of our ability to gain market share for any of our approved products, expectations about revenue growth, projections of expenses and revenue, our future manufacturing capacity, and whether we can return to profitability and the timing of any return to profitability.

All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from those implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties that are discussed in our press release that we issued today, as well as the documents that we filed with the SEC. Forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statements. Fourth quarter and full year 2022 results are not necessarily indicative of results for future periods.

With me on today's call are Denny Lanfear, CEO of Coherus; Dr. Theresa Lavallee, Chief Development Officer; Dr. Rosh Dias, Chief Medical Officer; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, Chief Financial Officer.